empagliflozin
empagliflozin: developed by 1 company · 13 clinical trials tracked.
empagliflozin evidence translation
What we can confirm
13 tracked trials
What it means
What to watch
Prepared research question
How could empagliflozin → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 4 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| ELI LILLY & Co (LLY) for the treatment of type 2 diabetes; to reduce the risk of … | Approved |
Clinical Trials (13)showing 10 most recent
The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD
Primary endpoint: Change in endothelium-dependent vasodilation as measured by flow mediated dilation (FMD)
The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus
Primary endpoint: Change in skeletal muscle mitochondrial oxidative capacity
A Randomised, Double-blind, Placebo-controlled Trial With an Open-label Extension to Assess the Pharmacokinetics, Safety, and Efficacy of Empagliflozin Tablets in Paediatric Patients With Chronic Kidney Disease (EMPA-KIDNEY® Kids)
Primary endpoint: Change from Day 1 to the Week 24 visit in urine albumin-creatinine (UACR) [mg/g]
Repurposing Empagliflozin for Duchenne Muscular Dystrophy - Associated Cardiomyopathy: a Pharmacokinetics, Safety and Proof-of-concept Study Among Children 6-18 Years of Age
Primary endpoint: Pharmacokinetics - apparent clearance (CL/F)
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
Primary endpoint: Percentage of participants who complete all study procedures
Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.
Primary endpoint: Questionnaire results
Evaluation of the Effectiveness of Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT Study).
Primary endpoint: Number of participants with diagnosis of cancer treatment-related cardiac dysfunction (CTRCD) at any time over the 12-month study period
Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase
Primary endpoint: Mild cognitive impairment (MCI) remission rate
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Empagliflozin in Patients With Acute Heart Failure
Primary endpoint: A hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, WHF during hospitalization, and urine output up to 48 hours after treatment initiation, assessed by the win ratio
Post Marketing Surveillance on Long Term Drug Use of JARDIANCE® Tablets in Patients With Chronic Heart Failure in Japan
Primary endpoint: Number of Subjects With Adverse Drug Reactions (ADRs)
Frequently asked questions
Who is developing empagliflozin?
empagliflozin is being developed by ELI LILLY & Co.
How many clinical trials involve empagliflozin?
BioSniper tracks 13 clinical trials involving empagliflozin.